Eli Lilly’s business segments
Eli Lilly and Company’s (LLY) business is divided into two segments: the Human Pharmaceutical segment and Elanco, the Animal Health segment.
The above chart compares Eli Lilly’s quarterly revenues by segment since the first quarter of 2017. Its overall revenue rose 7% at a constant exchange rate during the second quarter of 2018.
The Human Pharmaceutical segment contributes over 87% of Eli Lilly’s total revenue. During the second quarter, the segment reported revenue of $5.6 billion, an 8% YoY (year-over-year) rise in revenue compared to the second quarter of 2017.
At constant exchange rates, the Human Pharmaceutical segment reported an 8% rise in revenue during the quarter.
The segment’s US markets reported an 11% rise, while its European markets reported a 14% rise, and its Japanese markets reported a 6% rise. The sales from the rest of the world reported a 10% rise in the quarter.
Eli Lilly operates its Animal Health segment through Elanco. Elanco reported revenue of ~$792.1 million in the second quarter, nearly 12.5% of the company’s total revenue in the period. Elanco reported a 1% rise in revenue in the quarter driven by a 1% favorable impact of foreign exchange and a 2% favorable impact of prices offset by a 2% decrease in volumes.
At constant exchange rates, the Animal Health segment reported a 1% fall in revenue.
Eli Lilly announced in July that it had plans to separate the Elanco segment through a potential IPO.